Michael Gladstone - Net Worth and Insider Trading

Michael Gladstone Net Worth

The estimated net worth of Michael Gladstone is at least $12 Million dollars as of 2024-11-13. Michael Gladstone is the Director of Day One Biopharmaceuticals Inc and owns about 766,667 shares of Day One Biopharmaceuticals Inc (DAWN) stock worth over $12 Million. Details can be seen in Michael Gladstone's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Michael Gladstone has not made any transactions after 2022-06-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Michael Gladstone

To

Michael Gladstone Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michael Gladstone owns 2 companies in total, including Day One Biopharmaceuticals Inc (DAWN) , and Third Harmonic Bio Inc (THRD) .

Click here to see the complete history of Michael Gladstone’s form 4 insider trades.

Insider Ownership Summary of Michael Gladstone

Ticker Comapny Transaction Date Type of Owner
DAWN Day One Biopharmaceuticals Inc 2022-06-17 director
THRD Third Harmonic Bio Inc 2022-09-14 director

Michael Gladstone Latest Holdings Summary

Michael Gladstone currently owns a total of 1 stock. Michael Gladstone owns 766,667 shares of Day One Biopharmaceuticals Inc (DAWN) as of June 17, 2022, with a value of $12 Million.

Latest Holdings of Michael Gladstone

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DAWN Day One Biopharmaceuticals Inc 2022-06-17 766,667 15.64 11,990,672

Holding Weightings of Michael Gladstone


Michael Gladstone Form 4 Trading Tracker

According to the SEC Form 4 filings, Michael Gladstone has made a total of 1 transactions in Day One Biopharmaceuticals Inc (DAWN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Day One Biopharmaceuticals Inc is the acquisition of 766,667 shares on June 17, 2022, which cost Michael Gladstone around $12 Million.

Insider Trading History of Michael Gladstone

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Michael Gladstone Trading Performance

GuruFocus tracks the stock performance after each of Michael Gladstone's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael Gladstone is 36.42%. GuruFocus also compares Michael Gladstone's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael Gladstone within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Michael Gladstone's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Michael Gladstone

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 21.22 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 16.1 LIMIT LIMIT LIMIT LIMIT LIMIT

Michael Gladstone Ownership Network

Ownership Network List of Michael Gladstone

No Data

Ownership Network Relation of Michael Gladstone

Insider Network Chart

Michael Gladstone Owned Company Details

What does Day One Biopharmaceuticals Inc do?

Who are the key executives at Day One Biopharmaceuticals Inc?

Michael Gladstone is the director of Day One Biopharmaceuticals Inc. Other key executives at Day One Biopharmaceuticals Inc include Chief Medical Officer Samuel C. Blackman , COO & CFO and Secretary York Charles N Ii , and director & Chief Executive Officer Jeremy Bender .

Day One Biopharmaceuticals Inc (DAWN) Insider Trades Summary

Over the past 18 months, Michael Gladstone made no insider transaction in Day One Biopharmaceuticals Inc (DAWN). Other recent insider transactions involving Day One Biopharmaceuticals Inc (DAWN) include a net sale of 210,055 shares made by Samuel C. Blackman , a net sale of 114,587 shares made by Jeremy Bender , and a net sale of 71,268 shares made by York Charles N Ii .

In summary, during the past 3 months, insiders sold 88,748 shares of Day One Biopharmaceuticals Inc (DAWN) in total and bought 0 shares, with a net sale of 88,748 shares. During the past 18 months, 420,920 shares of Day One Biopharmaceuticals Inc (DAWN) were sold and 2,244,684 shares were bought by its insiders, resulting in a net purchase of 1,823,764 shares.

Day One Biopharmaceuticals Inc (DAWN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Day One Biopharmaceuticals Inc Insider Transactions

No Available Data

Michael Gladstone Mailing Address

Above is the net worth, insider trading, and ownership report for Michael Gladstone. You might contact Michael Gladstone via mailing address: 395 Oyster Point Blvd, Suite 217, South San Francisco Ca 94080.